Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

*A Phase 2 clinical trial of intravenously-administered Brilacidin for COVID-19 conducted at sites in the United States and Russa has since completed (n=120). The Company reported topline results that Brilacidin did not show a difference compared to placebo in reducing Time to Sustained Recovery Through Day 29, the study's primary endpoint. All planned data outputs, and additional post-hoc data analyses, are expected to be completed by the end of February 2022.*

https://www.marketscreener.com/quote/stock/INNOVATION-PHARMACEUTICAL-111313705/news/INNOVATION-PHARMACEUTICALS-INC-MANAGEMENT-S-DISCUSSION-AND-ANALYSIS-OF-FINANCIAL-CONDITION-AND-RES-39469169/